非肌层浸润性膀胱癌（NMIBC）内镜治疗后的复发率仍然很高。标准治疗包括膀胱内滴注化学毒性剂，例如丝裂霉素 C (MMC)，以减少复发。据推测，经尿道膀胱肿瘤切除术 (TURBT) 后立即预先给予膀胱内高温 MMC (HIVEC) 可能会增强其疗效，但人体试验的证据很少。这项试点研究探讨了使用传导性 HIVEC 系统 (Combat BRS) 进行 TURBT 后立即进行膀胱内 MMC 滴注的安全性。招募了诊断为乳头状膀胱肿瘤并计划进行 TURBT 的患者。在接受 HIVEC 治疗的 29 名患者中，术后额外发病率极低。大多数（79.3%）住院1天后出院，没有患者需要膀胱冲洗。有 6 起 I-II 级不良事件（20.7%）和 1 起 III 级事件（3.4%）。 3个月内未观察到复发，12个月复发率为4.5%。研究结果表明，TURBT 后立即注射 HIVEC MMC 是安全的。需要进一步研究来评估与标准冷 MMC 相比的长期疗效。患者摘要：非肌肉浸润性膀胱癌的治疗方法是通过尿道插入膀胱的内窥镜（称为 TURBT）切除肿瘤。我们测试了 TURBT 后立即用化疗药物（丝裂霉素 C）温热溶液治疗膀胱的安全性，因为这可以防止肿瘤复发。该治疗安全且耐受性良好。需要对更多患者进行进一步试验并进行更长时间的随访以确认结果。版权所有 © 2024 欧洲泌尿外科协会。由 Elsevier B.V. 出版。保留所有权利。

The recurrence rate following endoscopic treatment of non-muscle-invasive bladder cancer (NMIBC) remains high. Standard treatment includes intravesical instillation of chemotoxic agents such as mitomycin C (MMC) to reduce recurrence. It is postulated that upfront administration of hyperthermic intravesical MMC (HIVEC) immediately after transurethral resection of bladder tumour (TURBT) may enhance its efficacy, but evidence from human trials is scant. This pilot study explored the safety of immediate intravesical MMC instillation following TURBT using a conductive HIVEC system (Combat BRS). Patients diagnosed with papillary bladder tumours scheduled for TURBT were recruited. Among 29 patients treated with HIVEC, there was minimal additional postoperative morbidity. The majority (79.3%) were discharged after a hospital stay of 1 d, and no patient required bladder irrigation. There were six grade I-II adverse events (20.7%) and one grade III event (3.4%). No recurrences were observed within 3 mo, and the 12-mo recurrence rate was 4.5%. The study findings demonstrate that immediate HIVEC MMC instillation following TURBT is safe. Further research is needed to assess long-term efficacy in comparison to standard cold MMC. PATIENT SUMMARY: Non-muscle-invasive bladder cancer is treated with tumour removal via a telescope inserted into the bladder through the urethra (called TURBT). We tested the safety of treating the bladder with a warm solution of a chemotherapy drug (mitomycin C) immediately after TURBT, as this may prevent tumour recurrence. The treatment was safe and well tolerated. Further trials are needed with more patients and longer follow-up to confirm the results.Copyright © 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.